Legal Representation
Attorney
James R. Meyer
USPTO Deadlines
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 10, 2005 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jun 10, 2005 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Sep 24, 2004 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Sep 7, 2004 | I | PAPER RECEIVED | Loading... | |
| Sep 7, 2004 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Jul 21, 2004 | CFIT | O | CASE FILE IN TICRS | Loading... |
| Mar 4, 2004 | I | PAPER RECEIVED | Loading... | |
| Mar 2, 2004 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Mar 2, 2004 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Aug 29, 2003 | I | PAPER RECEIVED | Loading... | |
| Aug 29, 2003 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Aug 29, 2003 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 9, 2003 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| May 8, 2003 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Mar 24, 2003 | I | PAPER RECEIVED | Loading... | |
| Mar 24, 2003 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Mar 24, 2003 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 2, 2002 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 2, 2002 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 26, 2002 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 1, 2002 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 12, 2001 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Oct 2, 2001 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 30, 2001 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 16, 2001 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Jan 3, 2001 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 005
House mark for a line of pharmaceutical products for the treatment of diabetes, cardiovascular diseases, neurological diseases, psychiatric diseases, infectious diseases, cancer, endocrine diseases, gastrointestinal diseases, viral diseases and immune system enhancers
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005